期刊文献+

小剂量阿司匹林在2180例高血压病患者心脑血管事件一级预防中的作用 被引量:7

Low-Dose Aspirin Time-Release for the Primary Prevention of Cerebro-Cardiovascular Accidents in Hypertensive Patients——A Multicenter Randomized Controlled Clinical Study among 2 180 Individuals with Hypertention
下载PDF
导出
摘要 目的 探讨小剂量阿司匹林缓释片对高血压患者心脑血管事件一级预防的作用。方法 由湖南省心脑血管痛防治网络协作组组织其网络内的13家三甲和二甲医院参与完成前瞻性随机对照研究。2274例高血压患者被随机分为试验组和对照组,其中试验组1186例,在血压控制正常后给予肠溶阿司匹林缓释片50~100mg/d及常规降压治疗;对照组1088例,只给予常规降压治疗,观察两组患者心脑血管事件的发生情况。平均随访3.2年,最后2180例完成试验,其中试验组1151例,对照组1029例。结果试验组各事件的累积发病率为总事件3.6%、脑梗死2.1%、脑出血0.7%、心肌梗死0.2%、总死亡0.4%、因事件死亡0.2%,对照组分别为总事件5.2%、脑梗死3.6%、脑出血1.3%、心肌梗死0.9%、总死亡0.4%、因事件死亡0.3%。试验组和对照组相比,心肌梗死发病率降低,其相对危险度为0.204(95%可信区间为0.044~0.943),具有统计学差异(P〈0.05)。而两组的心脑血管事件总发生率及脑梗死、脑出血、因事件死亡等终点事件比较没有统计学差异(P〉0.05)。与对照组比,试验组发生心脑血管事件的相对危险度为0.701(95%可信区间为0.469~1.048),发生脑梗死的相对危险度为0.815(95%可信区间为0.470~1.412),发生脑出血的相对危险度为0.567(95%可信区间为0.235~1.368),因心脑血管事件死亡的相对危险度为3.645(95%可信区间为0.407~32.614),差异无统计学意义(P〉0.05)。结论 高血压患者常规降压治疗的同时加用小剂量阿司匹林缓释片可以显著降低心肌梗死的发生率,且未见增加脑出血的风险,可以起到一级预防的作用。 Aim To evaluate the effect of aspirin time-release on the incidence of cerebro-cardiovascular accidents in hypertensive patients.Methods This study was an opening, randomized, and controlled clinical prospective research, participated by 13 "the 3rd degree and grade A"hospitals and "the 2rid degree and grade A" hospitals which were organized by the eerebro-cardiovaseular disease interventional net of hunan province coordinating center.2 274 patients were randomly assigned to treatment group and control group,There are 1 286 patients in treated group assigned to aspirin 50 - 100 mg/d besides anfi-hy pertensive treatment,while 1 088 patients in control group received only routine anfi-hypertens'ive therapy.The average follow-up time was 3.2 years (range 1 -4 years). Finally 2 180 patients had completed the study which included 1 151 treated group patients and 1 029 control group patients.Results In treated group,the cumulative incidence risk of total eerebro-eardiovaseular accidents, cerebral infarction,cerebral hemorrhage, myocardial infarction, total death, death caused by cerebro-cardiovascular accidents was 3.6%, 2.1%, 0.7%, 0.2%, 0.4%, 0.2%,but in control group the cumulative incidence risk of each event was 5.2%, 3.6%, 1.3%, 0.9%, 0.4%, 0.3%.The study observed that active treatment obviously reduced the incidence of fatal and non-fatal acute myocardial infarctions ( P〈0.05), compared "with the controll group, the relative risk (95% confidence interval,95% CI) was 0.204 (0.044 - 0.943). But the relative risk of accidents, cerebra/infarction, cerebral hemorrhage was 0.701 (0.469 - 1.048), 0.815 (0.470- 1.412), 0.567 (0.235 - 1.368), respectively, Conclusions are nonsignificant. Furthermore, the relative risk of death caused by cerebro-cardiovascular accidents ,was 3.645 (0.407 - 32.614). Conclusions The active therapy with low-dose aspirin could significantly reduce the incidence of fatal and non-fatal acute myocardial infarctions in hypertensive patients. And there was no increased risk of stroke or bleeding. So it has effect on the primary prevention.
出处 《中国动脉硬化杂志》 CAS CSCD 2006年第3期233-236,共4页 Chinese Journal of Arteriosclerosis
基金 湖南省科技厅资助项目(0033Y1013-7)
关键词 内科学 阿司匹林 高血压痛 心脑血管事件 一级预防 相对危险度 Aspirin Hypertension Cerebro-Cardiovaseular Accidents Primary Prevention Risk
  • 相关文献

参考文献15

  • 1Chobanian AV< Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the joint national committee on prevention, detedtion, evaluation, and treatment of high blood pressure: the JNC 7 report[J]. JAMA, 2003, 289(19):2560-572
  • 2刘力生.2004年中国高血压防治指南(实用本)[J].中华心血管病杂志,2004,32(12):1060-1064. 被引量:2620
  • 3Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events[J]. Arch Intern Med, 2002, 162(19):2197-202
  • 4Gaziano JM, Skerrett PJ, Buring JE. Aspirin in the treatment and prevention of cardiovascular disease[J]. Haemostasis, 2000, 30(Suppl3):1-13
  • 5Boltri JM, Akerson MR, Vogel RL. Aspirin prophylaxis in patients at low risk for cardiovascular disease: a systematic review of all cause mortality[J]. J Fam Pract, 2002, 51(8):700-704
  • 6湖南省心脑血管病防治网络协作组.阿司匹林缓释片对2430例高危人群心脑血管事件发生率的影响[J].中国动脉硬化杂志,2003,11(5):446-450. 被引量:5
  • 7Patrono C. Aspirin: new cardiovascular uses for and old drug[J]. Am J Med, 2001, 110(1A): 62S-65S
  • 8US Department of Health and Human Services Public Health Service, Agency for Health Care Policy and Research. Post-stroke rehabilitation: assessment, referral, and patient management[J]. Clin Pract Guidel Quick Ref Guide Clin, 1995,16:1-32
  • 9Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, et al. 1999 update: ACC/AHA guidelines for the management of patients with actute myocardial infarction[J]. J Am Coll Cardiol, 1999, 34(3):890-911
  • 10Emsley HC, Tyrrell PJ. Inflammation and infection in clinical stroke[J]. J Cereb Blood Flow Metab, 2002, 22(12):1399-419

二级参考文献16

  • 1邓小戈,廖二元,伍汉文.血管紧张素转化酶抑制剂降血压与降蛋白尿和心脑血管事件的Meta分析[J].中国动脉硬化杂志,2001,9(3):241-244. 被引量:2
  • 2Weisman SM, Graham DY. Evalualion of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events.Arch Intern Med, 2002, 162 (19): 2 197-202.
  • 3Sanmuganathan PS, Ghahramatri P, Jeckson PR, Wallis EJ,Ramsay LE.Aspirin for primary prevention of coronary heart disease: safety and absolute benefit relsted to coronary risk derived from meta-analysis of randomised trials. Heart,2001, 85 (3): 265-271.
  • 4Gaziano JM, Skerrett PJ, Buring JE. Asprin in the treatment and prevention of cardiovascular disease . Haemostasis , 2000, 30 (Suppl3): 1-13.
  • 5Blood pressure, cholesterol, and stroke in easterm Asia. Eastern Stroke and Coronary Heart Disease Collaborative Research Group,Lancet ,1998,352: 1801-807.
  • 6De Schryver EL, Algra A, van Gijn J. Dipyridamole for preventing stroke and other vascular event in patients with vascular disease ( Cochrome Review). Cochrane Database Syst Rev, 2003, 1:CD001820.
  • 7SleightP. The HOPE(heart outcomes prevention evalution) studk. J Ren Ang Aldost Syst, 2000, 1 ( 1 ) : 18-20.
  • 8Boltri JM, Akerson MR, Vogel RL. Aspirin prophylaxis in patients at low risk for cardiovascular disease: a systematic review of all-cause mortality. J Farm Pract, 2002, 51 (8): 700-704.
  • 9Hayden M,Pignone M,Phillips C,Mulrow C.Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force. Ann Irtern Med, 2002 ,136 (2) : 161-172.
  • 10Patrono C. Aspirin: new cardiovascular uses for an old durg. Am J Med.2001, 110 (1A): 62S-65S.

共引文献2623

同被引文献52

引证文献7

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部